Genentech, A Member Of The Roche Group, Announced That The Phase Iii Imscin001 Study Evaluating A Subcutaneous Formulation Of Tecentriq (Atezolizumab) Met Its Co-Primary Endpoints. The Study Showed Non-Inferior Levels Of Tecentriq In The Blood (Pharmacokinetics), When Injected Subcutaneously, Compared With Intravenous (Iv) Infusion, In Cancer Immunotherapy-Na
